SCOPE-BD Recruitment

SCOPE-BD is a single-site, randomised, double-blind, placebo-controlled, parallel, phase IIb clinical trial, led by PI Dr. Brian Hallahan. The primary objective of the study is to investigate the efficacy of intravenous Scopolamine, compared to placebo, in reducing the severity of depressive episodes in individuals with bipolar disorder.

Study participation involves attendance for 4 IV infusion visits, as well as two brief follow up visits at UCHG. A number of psychometric tools are used in order to investigate aspects of cognition and affect; the results of these tests can be fed back to the patients’ clinical teams. Travel costs etc. will be covered by the study and can include accommodation in Galway for those travelling from further afield. 

Those interested should contact Ruán Kane (Clinical Research Assistant) on 086 008 1175 or at ruan.kane@nuigalway.ie

SCOPE-BD Information Leaflet & Consent Form